CRISPR Therapeutics
company in Basel, Switzerland
CRSP Nasdaq
ISIN CH0334081137 SEC CIK 1674416 LEI 506700O6IRRIQLT3W370
Follow CRISPR Therapeutics
Weekly email: filings, results
Revenue, last quarter
$12.7M
+1325.1% vs same quarter last year
Net income
−$111.4M
−4.7% vs same quarter last year
EPS, diluted
−$1.15
+1.7% vs same quarter last year
Operating cash flow
−$89.7M
−6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $3.5M | −$581.6M |
| FY24 | $37.3M | −$366.3M |
| FY23 | $371.2M | −$153.6M |
| FY22 | $1.2M | −$650.2M |
| FY21 | $915M | $377.7M |
| FY20 | $719K | −$348.9M |
| FY19 | $289.6M | $66.9M |
| FY18 | $3.1M | −$165M |
| FY17 | $41M | −$68.4M |
| FY16 | $5.2M | −$23.2M |
| FY15 | $247K | −$25.5M |
| FY14 | - | - |
| FY13 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −18933.6% | −16569.8% |
| FY24 | −1250.4% | −981.5% |
| FY23 | −60% | −41.4% |
| FY22 | −56190.4% | −54271.7% |
| FY21 | 40.8% | 41.3% |
| FY20 | −49295.5% | −48520.9% |
| FY19 | 16.1% | 23.1% |
| FY18 | −5087.8% | −5281.1% |
| FY17 | −157.7% | −166.7% |
| FY16 | −1319.3% | −448.8% |
| FY15 | −10416.6% | −10325.1% |
| FY14 | - | - |
| FY13 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$345.9M |
| FY24 | −$144.7M |
| FY23 | −$269.8M |
| FY22 | −$532.9M |
| FY21 | $457.3M |
| FY20 | −$256.7M |
| FY19 | $50M |
| FY18 | −$99M |
| FY17 | −$77.9M |
| FY16 | −$55.9M |
| FY15 | $58.3M |
| FY14 | - |
| FY13 | - |
- CRISPR Therapeutics
- Healthcare median
Show the numbers
| Year | CRISPR Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −16569.8% | −30.6% |
| FY24 | −981.5% | −47% |
| FY23 | −41.4% | −58% |
| FY22 | −54271.7% | −80.4% |
| FY21 | 41.3% | −71.9% |
| FY20 | −48520.9% | −62.2% |
| FY19 | 23.1% | −46.3% |
| FY18 | −5281.1% | −49.6% |
| FY17 | −166.7% | −45.9% |
| FY16 | −448.8% | −36% |
| FY15 | −10325.1% | −38.4% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |